Changes to Adjuvant Systemic Therapy in Breast Cancer: A Decade in Review
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference98 articles.
1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009
2. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node positive breast cancer — The results of 20 years of follow-up;Bonadonna;N Engl J Med,1995
3. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005
5. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer;Henderson;J Clin Oncol,2003
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Selenyum Dioksit ve Paklitaksel Kombinasyonunun MDA-MB-231 Meme Kanseri Hücre Hattı Üzerine Etkisinin Değerlendirilmesi;Sağlık Bilimlerinde Değer;2023-05-10
2. Emergence of novel targeting systems and conventional therapies for effective cancer treatment;Nano Drug Delivery Strategies for the Treatment of Cancers;2021
3. Incorporating competing risk theory into evaluations of changes in cancer survival: making the most of cause of death and routinely linked sociodemographic data;BMC Public Health;2020-06-26
4. Does minimum follow-up time post-diagnosis matter? An assessment of changing loss of life expectancy for people with cancer in Western Australia from 1982 to 2016;Cancer Epidemiology;2020-06
5. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer;Clinical and Translational Oncology;2020-05-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3